Aurobindo Pharma Limited announced the inauguration of TheraNym, one of India's largest dedicated biologics contract manufacturing organisations (CMO), through its subsidiary Theranym Biologics Private Limited. The facility was inaugurated on June 3, 2026, in the presence of Shri D. Sridhar Babu (Hon'ble Minister for IT, Industries & Commerce and Legislative Affairs of Telangana) and Shri Damodar Raja Narasimha (Minister for Science and Technology of Telangana).
Facility Specifications and Capabilities
The TheraNym Biologics facility is strategically located in Borapatla, approximately 45 minutes from Hyderabad's Financial District. The facility is equipped with:
- 15 KL bioreactors
- Advanced downstream processing suites
- Aseptic fill-finish capabilities
- Quality control laboratories
The facility has been designed to meet international regulatory standards and is intended to support both domestic and export markets, subject to applicable approvals and customer requirements.
Strategic Partnership and Customer Details
MSD (Merck & Co.) has joined as the anchor customer for TheraNym. The partnership is described as an "innovative partnership" that reflects a shared commitment to strengthening global access to critical biologic medicines. The facility adds meaningful capacity and capability to the MSD supply chain, enabling compliant and reliable supply of products to patients.
Management Commentary
Dr. Satakarni Makkapati, CEO Biologics and Director of Aurobindo Pharma Limited, stated that TheraNym represents "a defining moment in large-scale biologics manufacturing in India" and is positioned to serve the supply chains of leading global pharmaceutical companies.
Mr. Nithyananda Reddy, Vice Chairman and MD of Aurobindo Pharma, emphasized that TheraNym Biologics represents a strategic addition for contract manufacturing, building on the company's earlier foray into biosimilars with CuraTeQ.
Dr. Dave Maraldo, MSD Executive Vice President and President of MSD Manufacturing Division, commented that the partnership enables compliant and reliable supply of products to patients who need them most.
Government Support and Acknowledgments
The company expressed gratitude to the Government of Telangana for its support, specifically mentioning:
- Meeting with Hon'ble Chief Minister Shri Anumula Revanth Reddy prior to the inauguration
- Presence of two Telangana government ministers at the inauguration ceremony
- Telangana Life Sciences Policy
- Investment facilitation through T-Hub and Telangana State Industrial Infrastructure Corporation (TSIIC)
The company also acknowledged the transformative impact of Indian government policies including:
- Production Linked Incentive (PLI) scheme for pharmaceuticals
- National Biopharma Mission
- Biotechnology Industry Research Assistance Council (BIRAC)
Hyderabad Ecosystem Context
The release highlighted Hyderabad's position as India's premier pharmaceutical and biotechnology hub, noting:
- Over 800 pharmaceutical companies in the city
- Employment of more than 300,000 life sciences professionals
- Pharmaceutical exports exceeding USD 8 billion annually
- Genome Valley as one of Asia's densest concentrations of biologics R&D and manufacturing capability
Regulatory Disclosure
This disclosure is being submitted to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Forward-Looking Statements Disclaimer
The press release contains forward-looking statements relating to product characteristics, sales potential, strategic initiatives, and future business developments, with the company noting that actual results may differ materially from expectations.